A Topical BRAF-inhibiting Gel May Mitigate Acneiform Rash in Patients Receiving EGFR-targeted Therapy for Colorectal Cancer
April 27, 2025
April 27, 2025
PHILADELPHIA, Pennsylvania, April 27 [Category: Medical] -- The American Association for Cancer Research posted the following news release:
* * *
A Topical BRAF-inhibiting Gel May Mitigate Acneiform Rash in Patients Receiving EGFR-targeted Therapy for Colorectal Cancer
CHICAGO - Patients with colorectal cancer who had acneiform rash and applied LUT014 gel, an investigational topical BRAF inhibitor, were more likely to experience improvement of their rash co . . .
* * *
A Topical BRAF-inhibiting Gel May Mitigate Acneiform Rash in Patients Receiving EGFR-targeted Therapy for Colorectal Cancer
CHICAGO - Patients with colorectal cancer who had acneiform rash and applied LUT014 gel, an investigational topical BRAF inhibitor, were more likely to experience improvement of their rash co . . .